{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:30:07Z","timestamp":1770978607806,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-022-01800-1","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T18:09:03Z","timestamp":1662574143000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Anti-EGF nanobodies enhance the antitumoral effect of osimertinib and overcome resistance in non-small cell lung cancer (NSCLC) cellular models"],"prefix":"10.1007","volume":"39","author":[{"given":"Salvador","family":"Guardiola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Macarena","family":"S\u00e1nchez-Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Rosell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernest","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8239-9016","authenticated-orcid":false,"given":"Jordi","family":"Codony-Servat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,7]]},"reference":[{"key":"1800_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/caac.21254","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5\u201329.","journal-title":"CA Cancer J Clin"},{"issue":"5676","key":"1800_CR2","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"J Guillermo Paez","year":"2004","unstructured":"Guillermo Paez J, J\u00e4nne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497\u2013500.","journal-title":"Science"},{"key":"1800_CR3","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561\u20136.","journal-title":"Nature"},{"key":"1800_CR4","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","volume":"363","author":"EL Kwak","year":"2010","unstructured":"Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693\u2013703.","journal-title":"N Engl J Med"},{"key":"1800_CR5","doi-asserted-by":"publisher","first-page":"6169","DOI":"10.1158\/1078-0432.CCR-11-3265","volume":"18","author":"S Dogan","year":"2012","unstructured":"Dogan S, Shen R, Ang DC, Johnson ML, D\u2019Angelo SP, Paik PK, et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res. 2012;18:6169\u201377.","journal-title":"Clin Cancer Res"},{"key":"1800_CR6","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1158\/2159-8290.CD-16-1337","volume":"7","author":"EJ Jordan","year":"2017","unstructured":"Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 2017;7:596\u2013609.","journal-title":"Cancer Discov"},{"key":"1800_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"JD Bradley","year":"2015","unstructured":"Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16:187\u201399.","journal-title":"Lancet Oncol"},{"key":"1800_CR8","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1200\/JCO.2009.21.9618","volume":"28","author":"TJ Lynch","year":"2010","unstructured":"Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, et al. Cetuximab and first-line taxane\/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol. 2010;28:911\u20137.","journal-title":"J Clin Oncol"},{"key":"1800_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/13543784.2018.1415324","volume":"27","author":"C Kim","year":"2018","unstructured":"Kim C, Giaccone G. MEK inhibitors under development for treatment of non-small-cell lung cancer. Expert Opin Investig Drugs. 2018;27:17\u201330.","journal-title":"Expert Opin Investig Drugs"},{"key":"1800_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1023\/A:1015666024386","volume":"20","author":"M Kaur","year":"2002","unstructured":"Kaur M, Reed E, Sartor O, Dahut W, Figg WD. Suramin\u2019s development: what did we learn? Invest New Drugs Springer. 2002;20:209\u201319.","journal-title":"Invest New Drugs Springer"},{"key":"1800_CR11","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1158\/1078-0432.CCR-15-0855","volume":"22","author":"PC Rodriguez","year":"2016","unstructured":"Rodriguez PC, Popa X, Mart\u00ednez O, Mendoza S, Santiesteban E, Crespo T, et al. A phase III clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res. 2016;22:3782\u201390.","journal-title":"Clin Cancer Res"},{"key":"1800_CR12","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1016\/j.jtho.2016.08.132","volume":"11","author":"R Rosell","year":"2016","unstructured":"Rosell R, Neninger E, Nicolson M, Huber RM, Thongprasert S, Parikh PM, et al. Pathway targeted immunotherapy: rationale and evidence of durable clinical responses with a novel, EGF-directed agent for advanced NSCLC. J Thorac Oncol. 2016;11:1954\u201361.","journal-title":"J Thorac Oncol"},{"key":"1800_CR13","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.jtho.2018.04.030","volume":"13","author":"J Codony-Servat","year":"2018","unstructured":"Codony-Servat J, Garc\u00eda-Roman S, Molina-Vila M\u00c1, Bertran-Alamillo J, Gim\u00e9nez-Capit\u00e1n A, Viteri S, et al. Anti-epidermal growth factor vaccine antibodies enhance the efficacy of tyrosine kinase inhibitors and delay the emergence of resistance in EGFR mutant lung cancer cells. J Thorac Oncol. 2018;13:1324\u201337.","journal-title":"J Thorac Oncol"},{"key":"1800_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.lungcan.2021.12.014","volume":"164","author":"D Rodr\u00edguez-Abreu","year":"2022","unstructured":"Rodr\u00edguez-Abreu D, Cobo M, Garc\u00eda-Rom\u00e1n S, Viteri-Ram\u00edrez S, Jordana-Ariza N, Garc\u00eda-Pel\u00e1ez B, et al. The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC. Lung Cancer. 2022;164:8\u201313.","journal-title":"Lung Cancer"},{"key":"1800_CR15","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.tips.2019.10.004","volume":"40","author":"S Guardiola","year":"2019","unstructured":"Guardiola S, Varese M, S\u00e1nchez-Navarro M, Giralt E. A third shot at EGFR: new opportunities in cancer therapy. Trends Pharmacol Sci. 2019;40:941\u201355.","journal-title":"Trends Pharmacol Sci"},{"key":"1800_CR16","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3389\/fonc.2020.01182","volume":"10","author":"EY Yang","year":"2020","unstructured":"Yang EY, Shah K. Nanobodies: next generation of cancer diagnostics and therapeutics. Front Oncol. 2020;10:1182.","journal-title":"Front Oncol"},{"key":"1800_CR17","doi-asserted-by":"publisher","first-page":"13843","DOI":"10.1002\/anie.201807736","volume":"57","author":"S Guardiola","year":"2018","unstructured":"Guardiola S, Varese M, S\u00e1nchez-Navarro M, Vincke C, Teixid\u00f3 M, Garc\u00eda J, et al. Blocking EGFR activation with anti-EGF nanobodies via two distinct molecular recognition mechanisms. Angew Chem Int Ed Engl. 2018;57:13843\u20137.","journal-title":"Angew Chem Int Ed Engl"},{"key":"1800_CR18","doi-asserted-by":"publisher","first-page":"100887","DOI":"10.1016\/j.tranon.2020.100887","volume":"14","author":"J Codony-Servat","year":"2021","unstructured":"Codony-Servat J, Garc\u00eda-Roman S, Molina-Vila M\u00c1, Bertran-Alamillo J, Viteri S, d\u2019Hondt E, et al. Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells. Transl Oncol. 2021;14:100887.","journal-title":"Transl Oncol"},{"key":"1800_CR19","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1158\/2159-8290.CD-15-0063","volume":"5","author":"EM Tricker","year":"2015","unstructured":"Tricker EM, Xu C, Uddin S, Capelletti M, Ercan D, Ogino A, et al. Combined EGFR\/MEK inhibition prevents the emergence of resistance in EGFR-mutant lung cancer. Cancer Discov Cancer Discov. 2015;5:960\u201371.","journal-title":"Cancer Discov Cancer Discov"},{"key":"1800_CR20","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3390\/ph13060134","volume":"13","author":"S Guardiola","year":"2020","unstructured":"Guardiola S, Varese M, Taul\u00e9s M, D\u00edaz-Lobo M, Garc\u00eda J, Giralt E. Probing the kinetic and thermodynamic fingerprints of anti-EGF nanobodies by surface plasmon resonance. Pharmaceuticals. 2020;13:134.","journal-title":"Pharmaceuticals"},{"key":"1800_CR21","doi-asserted-by":"publisher","first-page":"340","DOI":"10.21037\/tlcr.2019.08.22","volume":"8","author":"J Codony-Servat","year":"2019","unstructured":"Codony-Servat J, Viteri S, Codony-Servat C, Ito M, Bracht JWP, Berenguer J, et al. Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines. Transl Lung Cancer Res. 2019;8:340.","journal-title":"Transl Lung Cancer Res"},{"key":"1800_CR22","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1097\/CAD.0000000000001242","volume":"33","author":"F Qu","year":"2022","unstructured":"Qu F, Zhou Y, Yu W. A review of research progress on mechanisms and overcoming strategies of acquired osimertinib resistance. Anticancer Drugs. 2022;33:e76.","journal-title":"Anticancer Drugs"},{"key":"1800_CR23","doi-asserted-by":"publisher","first-page":"8522","DOI":"10.3390\/ijms22168522","volume":"22","author":"R Nanamiya","year":"2021","unstructured":"Nanamiya R, Saito-Koyama R, Miki Y, Inoue C, Asavasupreechar T, Abe J, et al. EphB4 as a novel target for the EGFR-independent suppressive effects of osimertinib on cell cycle progression in non-small cell lung cancer. Int J Mol Sci. 2021;22:8522.","journal-title":"Int J Mol Sci"},{"key":"1800_CR24","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/cbic.201500525","volume":"17","author":"S Guardiola","year":"2016","unstructured":"Guardiola S, D\u00edaz-Lobo M, Seco J, Garc\u00eda J, Nevola L, Giralt E. Peptides targeting EGF block the EGF-EGFR interaction. ChemBioChem. 2016;17:702\u201311.","journal-title":"ChemBioChem"},{"key":"1800_CR25","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/cbic.201700519","volume":"19","author":"S Guardiola","year":"2018","unstructured":"Guardiola S, Seco J, Varese M, D\u00edaz-Lobo M, Garc\u00eda J, Teixid\u00f3 M, et al. Toward a novel drug to target the EGF-EGFR interaction: design of metabolically stable bicyclic peptides. ChemBioChem. 2018;19:76\u201384.","journal-title":"ChemBioChem"},{"key":"1800_CR26","first-page":"1","volume":"18","author":"T Chen","year":"2020","unstructured":"Chen T, Liu X, Hong H, Wei H. Novel single-domain antibodies against the EGFR domain III epitope exhibit the anti-tumor effect. J Transl Med BioMed Central. 2020;18:1\u201316.","journal-title":"J Transl Med BioMed Central"},{"key":"1800_CR27","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jconrel.2012.11.007","volume":"165","author":"I Altintas","year":"2013","unstructured":"Altintas I, Heukers R, van der Meel R, Lacombe M, Amidi M, van Bergen En Henegouwen PM, et al. Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells. J Control Release. 2013;165:110\u20138.","journal-title":"J Control Release"},{"key":"1800_CR28","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/smll.201302383","volume":"10","author":"KD Wegner","year":"2014","unstructured":"Wegner KD, Lind\u00e9n S, Jin Z, Jennings TL, el Khoulati R, van Bergen en Henegouwen PM, et al. Nanobodies and nanocrystals: highly sensitive quantum dot-based homogeneous FRET immunoassay for serum-based EGFR detection. Small. 2014;10:734\u201340.","journal-title":"Small"},{"key":"1800_CR29","doi-asserted-by":"publisher","first-page":"25597","DOI":"10.18632\/oncotarget.25390","volume":"9","author":"S Albert","year":"2018","unstructured":"Albert S, Arndt C, Koristka S, Berndt N, Bergmann R, Feldmann A, et al. From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo. Oncotarget. 2018;9:25597.","journal-title":"Oncotarget"},{"key":"1800_CR30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jconrel.2016.03.014","volume":"229","author":"D van Pbaa","year":"2016","unstructured":"van Pbaa D, Boonstra MC, Slooter MD, Heukers R, Stammes MA, Snoeks TJA, et al. EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer. J Control Release. 2016;229:93\u2013105.","journal-title":"J Control Release"},{"key":"1800_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-020-01613-0","volume":"20","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Wu L, Liu S, Chen Q, Zeng L, Chen X, et al. Targeted nanobody complex enhanced photodynamic therapy for lung cancer by overcoming tumor microenvironment. Cancer Cell Int. 2020;20:1\u201316.","journal-title":"Cancer Cell Int"},{"key":"1800_CR32","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/15384047.2015.1016662","volume":"16","author":"Z-H Liu","year":"2015","unstructured":"Liu Z-H, Dai X-M, Du B. Hes1: a key role in stemness, metastasis and multidrug resistance. Cancer Biol Ther. 2015;16:353\u20139.","journal-title":"Cancer Biol Ther"},{"key":"1800_CR33","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1158\/1078-0432.CCR-12-1558","volume":"19","author":"LA Byers","year":"2013","unstructured":"Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013;19:279\u201390.","journal-title":"Clin Cancer Res"},{"key":"1800_CR34","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/ng.2330","volume":"44","author":"Z Zhang","year":"2012","unstructured":"Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 2012;44:852\u201360.","journal-title":"Nat Genet"},{"key":"1800_CR35","doi-asserted-by":"publisher","first-page":"e7346","DOI":"10.1097\/MD.0000000000007346","volume":"96","author":"X Zhang","year":"2017","unstructured":"Zhang X, Tian T, Sun W, Liu C, Fang X. Bmi-1 overexpression as an efficient prognostic marker in patients with nonsmall cell lung cancer. Medicine. 2017;96:e7346.","journal-title":"Medicine"},{"key":"1800_CR36","doi-asserted-by":"crossref","first-page":"153303382110706","DOI":"10.1177\/15330338211070689","volume":"21","author":"R Wang","year":"2022","unstructured":"Wang R, Fan H, Sun M, Lv Z, Yi W. Roles of BMI1 in the initiation, progression, and treatment of hepatocellular carcinoma. Technol Cancer Res Treat. 2022;21:15330338211070688.","journal-title":"Technol Cancer Res Treat"},{"key":"1800_CR37","first-page":"757","volume":"10","author":"Z Fang","year":"2020","unstructured":"Fang Z, Lin M, Li C, Liu H, Gong C. A comprehensive review of the roles of E2F1 in colon cancer. Am J Cancer Res. 2020;10:757.","journal-title":"Am J Cancer Res"},{"key":"1800_CR38","doi-asserted-by":"publisher","first-page":"407","DOI":"10.4161\/cc.6.4.3855","volume":"6","author":"RU J\u00e4nicke","year":"2007","unstructured":"J\u00e4nicke RU, Sohn D, Essmann F, Schulze-Osthoff K. The multiple battles fought by anti-apoptotic p21. Cell Cycle. 2007;6:407\u201313.","journal-title":"Cell Cycle"},{"key":"1800_CR39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.dnarep.2016.04.008","volume":"42","author":"A Karimian","year":"2016","unstructured":"Karimian A, Ahmadi Y, Yousefi B. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair DNA Repair (Amst). 2016;42:63\u201371.","journal-title":"DNA Repair DNA Repair (Amst)"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-022-01800-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-022-01800-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-022-01800-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T20:29:33Z","timestamp":1667334573000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-022-01800-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,7]]},"references-count":39,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1800"],"URL":"https:\/\/doi.org\/10.1007\/s12032-022-01800-1","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,7]]},"assertion":[{"value":"14 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.G., M.S.-N., E.G., J.C.-S., R.R. declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"195"}}